Peetz Christopher 4

What Happened
Christopher Peetz, a non-employee director of Arcutis Biotherapeutics (ARQT), received awards on July 15, 2026 totaling 38,811 shares (4,315 RSUs and two derivative awards of 21,486 and 13,010 underlying shares). All grants show a $0 acquisition price (standard for RSU/option awards); no cash changed hands. These are award/option grants (Form 4 code A) rather than purchases or sales.

Key Details

• Transaction date: July 15, 2026; filing date: July 17, 2026 (filed two business days after the transaction).
• Grants reported: 4,315 RSUs (F1); 21,486 derivative awards (F4); 13,010 derivative awards (F3). Total = 38,811 shares.
• Reported price: $0.00 (grants/awards). Total cash value at grant not reported on Form 4.
• Vesting highlights:
  • 4,315 RSUs vest on the earlier of June 5, 2027 or immediately before the next annual meeting, subject to continued service (F1).
  • 21,486 underlying shares vest 100% on the earlier of June 5, 2027 or immediately before the next annual meeting, subject to continued service (F4).
  • 13,010 underlying shares vest in thirds annually beginning July 15, 2026, and are fully vested on the fourth anniversary of that date, subject to continued service (F3).
• Trust holdings: Footnote (F2) notes shares held by The Peetz Family Trust (he is a trustee and disclaims beneficial ownership except for pecuniary interest).
• Shares owned after transaction: not specified in the summary data provided in your request.

Context
These are standard director compensation awards (RSUs and option-style derivative grants) that convert to or permit purchase of common stock only if and when they vest/exercise under the schedules above. They are not sales or purchases in the open market and do not indicate an immediate change in market exposure (no immediate sale or cashless exercise reported). The filing appears timely (filed two days after the grants).